The Milner Therapeutics Institute, University of Cambridge. Set up to bring together pharmaceutical companies and researchers in Cambridge to study and develop better therapies for some of today’s most globally devastating diseases.
The Milner Therapeutics Institute, currently being constructed, will open in early 2018 and is situated within the new Capella Building on the Cambridge Biomedical Campus. The Institute will have space for senior and junior scientists to set up independent research groups and also communally accessible facilities, such as robotics and bioinformatics. The building of the Institute was made possible by a £5 million donation from entrepreneur Jonathan Milner, a former member of Professor Kouzarides' research group. In 1998 they founded biotechnology company Abcam, which has gone on to employ more than 800 people and supply products to 64 per cent of researchers globally.
The Milner Therapeutics Consortium is hosted at the Gurdon Institute until the new building is complete. It connects academic scientists and institutions in Cambridge with the pharmaceutical industry, to develop the therapeutic potential of their research. The Consortium, which has been operational since June 2015, is based on a partnership between three academic centres, Cambridge University, Sanger Institute and Babraham Institute, with four pharmaceutical companies, Astex, AstraZeneca, GlaxoSmithKline and Shionogi.
The Therapeutics Consortium and the Milner Institute are led by Professor Tony Kouzarides, formerly deputy director of the university's Gurdon Institute.
Professor Kouzarides said: “We hope many more pharmaceutical companies will join our Consortium and believe this form of partnership is a model for how academic institutions and industry can work together to deliver better medicines.
Fill in this form to contact the site owners.